JP2012224636A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012224636A5 JP2012224636A5 JP2012166700A JP2012166700A JP2012224636A5 JP 2012224636 A5 JP2012224636 A5 JP 2012224636A5 JP 2012166700 A JP2012166700 A JP 2012166700A JP 2012166700 A JP2012166700 A JP 2012166700A JP 2012224636 A5 JP2012224636 A5 JP 2012224636A5
- Authority
- JP
- Japan
- Prior art keywords
- glucan
- conjugate according
- conjugate
- laminarin
- bacterial toxoid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims 21
- 229920002498 Beta-glucan Polymers 0.000 claims 19
- 229920001503 Glucan Polymers 0.000 claims 5
- 230000001580 bacterial effect Effects 0.000 claims 5
- DBTMGCOVALSLOR-DEVYUCJPSA-N (2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 claims 4
- 229920001543 Laminarin Polymers 0.000 claims 4
- 239000005717 Laminarin Substances 0.000 claims 4
- 230000002538 fungal effect Effects 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- 229960005486 vaccine Drugs 0.000 claims 3
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims 2
- 108091005804 Peptidases Proteins 0.000 claims 2
- 239000004365 Protease Substances 0.000 claims 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 2
- 230000001681 protective effect Effects 0.000 claims 2
- 102100024023 Histone PARylation factor 1 Human genes 0.000 claims 1
- 101001047783 Homo sapiens Histone PARylation factor 1 Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 239000003429 antifungal agent Substances 0.000 claims 1
- 210000002421 cell wall Anatomy 0.000 claims 1
- 244000053095 fungal pathogen Species 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0211118.5A GB0211118D0 (en) | 2002-05-15 | 2002-05-15 | Vaccines |
| GB0211118.5 | 2002-05-15 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009294467A Division JP2010131017A (ja) | 2002-05-15 | 2009-12-25 | グルカンベースのワクチン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012224636A JP2012224636A (ja) | 2012-11-15 |
| JP2012224636A5 true JP2012224636A5 (enExample) | 2013-07-18 |
| JP5684758B2 JP5684758B2 (ja) | 2015-03-18 |
Family
ID=9936711
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004505087A Expired - Fee Related JP5110767B2 (ja) | 2002-05-15 | 2003-05-15 | グルカンベースのワクチン |
| JP2009294467A Pending JP2010131017A (ja) | 2002-05-15 | 2009-12-25 | グルカンベースのワクチン |
| JP2012166700A Expired - Fee Related JP5684758B2 (ja) | 2002-05-15 | 2012-07-27 | グルカンベースのワクチン |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004505087A Expired - Fee Related JP5110767B2 (ja) | 2002-05-15 | 2003-05-15 | グルカンベースのワクチン |
| JP2009294467A Pending JP2010131017A (ja) | 2002-05-15 | 2009-12-25 | グルカンベースのワクチン |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US20050208079A1 (enExample) |
| EP (2) | EP1891970B1 (enExample) |
| JP (3) | JP5110767B2 (enExample) |
| AT (2) | ATE497781T1 (enExample) |
| AU (1) | AU2003241104A1 (enExample) |
| CA (2) | CA2485847C (enExample) |
| CY (1) | CY1108234T1 (enExample) |
| DE (2) | DE60320979D1 (enExample) |
| DK (1) | DK1506009T3 (enExample) |
| ES (1) | ES2306871T3 (enExample) |
| GB (1) | GB0211118D0 (enExample) |
| PT (1) | PT1506009E (enExample) |
| SI (1) | SI1506009T1 (enExample) |
| WO (1) | WO2003097091A2 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7507724B2 (en) * | 2001-01-16 | 2009-03-24 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
| US7906492B2 (en) | 2001-01-16 | 2011-03-15 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
| US8071552B2 (en) * | 2004-04-05 | 2011-12-06 | Universite Bordeaux 2 | Peptides and peptidomimetics binding to CD23 |
| GB0420466D0 (en) * | 2004-09-14 | 2004-10-20 | Cassone Antonio | Anti-glucan antibodies |
| PL2878307T3 (pl) | 2005-06-27 | 2020-01-31 | Glaxosmithkline Biologicals S.A. | Kompozycja immunogenna |
| WO2007084661A2 (en) * | 2006-01-17 | 2007-07-26 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
| US8323644B2 (en) * | 2006-01-17 | 2012-12-04 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
| US20090053221A1 (en) * | 2006-01-17 | 2009-02-26 | Cheung Nai-Kong V | Immune response enhancing glucan |
| WO2007127668A2 (en) * | 2006-04-26 | 2007-11-08 | Wyeth | Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations |
| WO2009134891A2 (en) * | 2008-04-29 | 2009-11-05 | Immunexcite, Inc. | Immunomodulating compositions and methods of use thereof |
| US9457047B2 (en) | 2006-11-06 | 2016-10-04 | Whitehead Institute | Immunomodulating compositions and methods of use thereof |
| ES2397186T3 (es) * | 2006-11-06 | 2013-03-05 | Whitehead Institute | Composiciones inmunomoduladoras y métodos para su uso |
| AU2013203785B2 (en) * | 2006-11-06 | 2016-11-17 | Immunexcite, Inc. | Immunomodulating compositions and methods of use thereof |
| JP4687644B2 (ja) | 2006-12-22 | 2011-05-25 | 富士ゼロックス株式会社 | 画像処理装置、画像読取装置及び画像形成装置 |
| US9439954B2 (en) | 2007-11-26 | 2016-09-13 | Glaxosmithkline Biologicals Sa | Conjugated beta-1,3-linked glucans |
| CA2706617A1 (en) † | 2007-11-26 | 2009-06-25 | Novartis Ag | Adjuvanted glucans |
| US20110236489A1 (en) | 2008-09-18 | 2011-09-29 | Novartis Ag | Vaccine adjuvant combinations |
| NL1036661C2 (en) | 2009-03-04 | 2010-09-07 | Serrix B V | Anti-fungal compounds & compositions. |
| JP2012520289A (ja) * | 2009-03-10 | 2012-09-06 | パルメッド テバ リミテッド | 新規なコプリヌス・コマトゥスおよびトレメッラ・メセンテリカキノコ菌株、それらの生産物および抽出物、ならびにそれらを含む組成物 |
| CN102740882A (zh) | 2009-08-27 | 2012-10-17 | 诺华有限公司 | 含有铝、寡核苷酸和聚阳离子的佐剂 |
| ES2443952T3 (es) | 2009-09-02 | 2014-02-21 | Novartis Ag | Composiciones inmunógenas que incluyen moduladores de la actividad de TLR |
| WO2011035205A2 (en) | 2009-09-18 | 2011-03-24 | Calmune Corporation | Antibodies against candida, collections thereof and methods of use |
| EA201291091A1 (ru) * | 2010-05-14 | 2013-05-30 | Олтек, Инк. | Компоненты клеточной стенки дрожжей и их обнаружение |
| CN105999275A (zh) | 2010-09-01 | 2016-10-12 | 诺华有限公司 | 免疫增强剂吸附不溶性金属离子 |
| US9618508B2 (en) | 2010-12-14 | 2017-04-11 | Glaxosmithkline Biologicals Sa | Flow cytometry analysis of materials adsorbed to metal salts |
| US20140112950A1 (en) | 2011-03-02 | 2014-04-24 | Manmohan Singh | Combination vaccines with lower doses of antigen and/or adjuvant |
| US9149541B2 (en) | 2011-07-08 | 2015-10-06 | Novartis Ag | Tyrosine ligation process |
| JP6170932B2 (ja) | 2011-11-07 | 2017-07-26 | ノバルティス アーゲー | spr0096抗原およびspr2021抗原を含むキャリア分子 |
| HRP20161354T1 (hr) | 2012-03-07 | 2016-12-02 | Glaxosmithkline Biologicals Sa | Argininske soli agonista tlr7 |
| JP2015510872A (ja) | 2012-03-07 | 2015-04-13 | ノバルティス アーゲー | Streptococcuspneumoniae抗原の増強された製剤 |
| US9375471B2 (en) | 2012-03-08 | 2016-06-28 | Glaxosmithkline Biologicals Sa | Adjuvanted formulations of booster vaccines |
| US10092646B2 (en) * | 2012-04-30 | 2018-10-09 | Biothera, Inc. | Compositions and methods for beta-glucan immunotherapy |
| TR201807340T4 (tr) | 2013-02-01 | 2018-06-21 | Glaxosmithkline Biologicals Sa | Çan benzeri reseptör agonistleri içeren immünolojik kompozisyonların intradermal yoldan verilmesi. |
| CN103083663B (zh) * | 2013-02-04 | 2014-12-10 | 江苏省农业科学院 | 一种免疫增强剂、灭活疫苗及其制备方法 |
| US20160017062A1 (en) | 2013-03-12 | 2016-01-21 | Wellstat Vaccines, Llc | Antibodies targeted to fungal cell wall polysaccharides |
| CN105593238B (zh) | 2013-07-11 | 2020-09-08 | 诺华股份有限公司 | 使用微生物转谷氨酰胺酶进行赖氨酸特异性化学酶法蛋白质修饰 |
| US9885726B2 (en) * | 2013-12-05 | 2018-02-06 | Biothera, Inc. | β-glucan assay methods |
| ES2857557T3 (es) * | 2015-01-26 | 2021-09-29 | Kaleido Biosciences Inc | Compuestos terapéuticos de glicano y métodos relacionados de los mismos |
| CN104771498A (zh) * | 2015-03-13 | 2015-07-15 | 臧海阳 | 一种治疗热毒蕴结型痄腮的中药组合物 |
| US11815435B2 (en) | 2017-02-24 | 2023-11-14 | Hibercell, Inc. | Beta glucan immunopharmacodynamics |
| KR102795692B1 (ko) * | 2018-01-19 | 2025-04-16 | 밀테니 비오텍 비.브이. & 씨오. 케이지 | 키메라 항원 수용체를 발현하는 조절 t 세포 |
| US11701417B2 (en) * | 2019-03-27 | 2023-07-18 | West Virginia University | Vaccine formulation to protect against pertussis |
| WO2023002252A1 (en) | 2021-07-21 | 2023-01-26 | Bioatlantis Limited | Composition comprising beta-glucans and alpha-fucans for improving gut health and animal performance and methods of making the same |
| AU2023225283A1 (en) | 2022-02-28 | 2024-08-22 | Tridem Bioscience Gmbh & Co Kg | A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN. |
| EP4486387A1 (en) | 2022-02-28 | 2025-01-08 | Tridem Bioscience GmbH & Co KG | A conjugate consisting of or comprising at least a ss-glucan or a mannan |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE466289B (sv) * | 1984-09-19 | 1992-01-27 | James Hoffman | Makrofagstimulerande komposition jaemte foerfarande foer dess framstaellning |
| JPS6383012A (ja) * | 1986-09-26 | 1988-04-13 | Nonogawa Shoji:Kk | 化粧料 |
| JPH05503952A (ja) * | 1989-09-08 | 1993-06-24 | アルファ ベータ テクノロジー,インコーポレイティッド | 可溶性グルカン類の製造方法 |
| EP0471954A3 (en) | 1990-08-13 | 1993-03-03 | American Cyanamid Company | Immunogenic conjugates of nontoxic oligosaccharide derived from bordetella pertussis lipooligosaccharide |
| US5153312A (en) * | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
| ATE280235T1 (de) * | 1993-03-05 | 2004-11-15 | Wyeth Corp | Plasmid zur herstellung von crm-protein und diphtherie-toxin |
| CN1094288A (zh) * | 1993-04-23 | 1994-11-02 | 福建省微生物研究所 | 利用红色诺卡氏菌制造细胞壁骨架粉末的方法 |
| NO300692B1 (no) | 1994-04-29 | 1997-07-07 | Biotec Mackzymal As | Solubilisert forgrenet ß-1,3-glukan og anvendelse derav samt anvendelse av usolubilisert forgrenet ß-1,3-glukan |
| US6309642B1 (en) * | 1997-04-28 | 2001-10-30 | The Research And Development Institute, Inc. | Peptides which mimic candida carbohydrate epitopes and their use in a vaccine |
| AUPN166195A0 (en) * | 1995-03-13 | 1995-04-06 | Norvet Research Pty Limited | Process for glucan extraction |
| JPH09309842A (ja) * | 1996-05-20 | 1997-12-02 | Kureha Chem Ind Co Ltd | 新規な生理活性物質、その製造方法及び医薬組成物 |
| AU760669B2 (en) * | 1998-04-28 | 2003-05-22 | Galenica Pharmaceuticals, Inc. | Polysaccharide-antigen conjugates |
| US6248329B1 (en) * | 1998-06-01 | 2001-06-19 | Ramaswamy Chandrashekar | Parasitic helminth cuticlin nucleic acid molecules and uses thereof |
| GB9925559D0 (en) * | 1999-10-28 | 1999-12-29 | Smithkline Beecham Biolog | Novel method |
| JP4230635B2 (ja) | 2000-02-29 | 2009-02-25 | 富士フイルム株式会社 | デジタルカメラ |
-
2002
- 2002-05-15 GB GBGB0211118.5A patent/GB0211118D0/en not_active Ceased
-
2003
- 2003-05-15 DE DE60320979T patent/DE60320979D1/de not_active Expired - Lifetime
- 2003-05-15 CA CA2485847A patent/CA2485847C/en not_active Expired - Fee Related
- 2003-05-15 EP EP07075796A patent/EP1891970B1/en not_active Expired - Lifetime
- 2003-05-15 DE DE60336027T patent/DE60336027D1/de not_active Expired - Lifetime
- 2003-05-15 SI SI200331275T patent/SI1506009T1/sl unknown
- 2003-05-15 PT PT03730424T patent/PT1506009E/pt unknown
- 2003-05-15 US US10/514,483 patent/US20050208079A1/en not_active Abandoned
- 2003-05-15 CA CA2830619A patent/CA2830619A1/en not_active Abandoned
- 2003-05-15 AT AT07075796T patent/ATE497781T1/de not_active IP Right Cessation
- 2003-05-15 ES ES03730424T patent/ES2306871T3/es not_active Expired - Lifetime
- 2003-05-15 WO PCT/IB2003/002460 patent/WO2003097091A2/en not_active Ceased
- 2003-05-15 DK DK03730424T patent/DK1506009T3/da active
- 2003-05-15 AT AT03730424T patent/ATE395080T1/de active
- 2003-05-15 AU AU2003241104A patent/AU2003241104A1/en not_active Abandoned
- 2003-05-15 JP JP2004505087A patent/JP5110767B2/ja not_active Expired - Fee Related
- 2003-05-15 EP EP03730424A patent/EP1506009B1/en not_active Expired - Lifetime
-
2007
- 2007-02-01 US US11/701,250 patent/US7824688B2/en not_active Expired - Fee Related
-
2008
- 2008-07-31 CY CY20081100809T patent/CY1108234T1/el unknown
-
2009
- 2009-12-25 JP JP2009294467A patent/JP2010131017A/ja active Pending
-
2010
- 2010-08-11 US US12/854,248 patent/US8398990B2/en not_active Expired - Fee Related
-
2012
- 2012-07-27 JP JP2012166700A patent/JP5684758B2/ja not_active Expired - Fee Related
-
2013
- 2013-02-26 US US13/777,903 patent/US8679506B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012224636A5 (enExample) | ||
| JP2012072157A5 (enExample) | ||
| WO2011028888A3 (en) | Methods of reducing virucidal activity in pcv-2 compositions and pcv-2 compositions with an improved immunogenicity | |
| JP2010535814A5 (enExample) | ||
| WO2007095976A3 (de) | Adjuvanz in form einer lipid-modifizierten nukleinsäure | |
| WO2009039229A3 (en) | Method of conferring a protective immune response to norovirus | |
| MX342684B (es) | Regimen de dosificacion escalante para efectuar la perdida de peso y el tratamiento de obesidad. | |
| EP2762165A3 (en) | Composition comprising a complexed (m)RNA and a naked mRNA for providing or enhancing an immunostimulatory response in a mammal and uses thereof | |
| NO20083722L (no) | Immunogen sammensetning | |
| WO2009051837A3 (en) | Vaccine nanotechnology | |
| WO2008083174A3 (en) | Compositions and methods for the treatment of infections and tumors | |
| JP2010215657A5 (enExample) | ||
| WO2011156774A3 (en) | Multivalent glycopeptide constructs and uses thereof | |
| WO2009090670A8 (en) | Stabilized sustained release composition of bupropion hydrochloride and process for preparing the same | |
| WO2017041100A3 (en) | Vaccine compositions having improved stability and immunogenicity | |
| MY166172A (en) | Non-lipidated variants of neisseria meningitidis orf2086 antigens | |
| WO2007084661A3 (en) | Therapy-enhancing glucan | |
| WO2006030318A3 (en) | PROTECTIVE ANTI-GLUCAN ANTIBODIES WITH PREFERENCE FOR β-1,3-GLUCANS | |
| WO2007105115A3 (en) | Compositions and methods for immunisation using cd1d ligands | |
| WO2011060372A3 (en) | Factor viii b cell epitope variants having reduced immunogenicity | |
| JP2008535798A5 (enExample) | ||
| WO2013188627A3 (en) | Cationic lipid vaccine compositions and methods of use | |
| JP2011504535A5 (enExample) | ||
| CA2816999A1 (en) | Compositions and methods for nanopolymer-based nucleic acid delivery | |
| WO2011047837A3 (de) | Schmelzgranuliertes cinacalcet |